Edit
Summit Therapeutics
http://www.summitplc.com/Last activity: 09.09.2024
Active - Reference to Summit Therapeutics
We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.
Location: United States, Massachusetts, Cambridge
Investors 1
| Date | Name | Website |
| - | Oxford Uni... | innovation... |
Mentions in press and media 8
| Date | Title | Description |
| 12.09.2024 | A New Dawn in Lung Cancer Treatment: Ivonescimab's Promising Phase II Results | In the ever-evolving landscape of cancer treatment, a new player has emerged. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, is making waves in the fight against non-small cell lung cancer (NSCLC). Recently presented at the 25t... |
| 09.09.2024 | Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024 | HONG KONG, Sept. 9, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combinati... |
| 08.09.2024 | Perioperative Ivonescimab (PD-1/VEGF) for NSCLC Demonstrated Clinically Significant Phase II Results, Presented in Oral Session at WCLC 2024 | HONG KONG, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926. HK) announced that its internally developed PD-1/VEGF bispecific antibody ivonescimab showed clinically significant results from a Phase II study, either as a monotherapy or in combinati... |
| 15.08.2024 | Ivonescimab (PD-1/VEGF) Received Priority Review from China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC | The Second Indication of Ivonescimab in NSCLC 2L+ EGFRm NSCLC Already Approved in May 2024 HONG KONG, Aug. 15, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced that the National Center for Drug Evaluatio... |
| 01.06.2024 | Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemo... | Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Rati... |
| 05.10.2020 | With Covid-19 mucking the tires, Robert Duggan throws another $50M behind his big antibiotics play | Robert Duggan is upping his ante on Summit Therapeutics. The billionaire investor quietly bid up to 65% of the small antibiotic developer before making himself CEO earlier this year and legally moving the company f... |
| 18.06.2019 | Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO | → Bob Nelsen-backed longevity startup Unity $UBX on Tuesday unveiled the first ever in-human data on its drug, UBX0101, which is designed to delay the aging process by snuffing senescent (old) cells. The first part (A) of the sm... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |